Alembic Pharmaceuticals informs about press release

26 Dec 2017 Evaluate

Alembic Pharmaceuticals has informed that their Associate Company, Rhizen Pharmaceuticals S.A. (Rhizen) has released a Press Release announcing that the USFDA has granted Orphan-Drug Designation for Tenalisib (RP6530). Couple of weeks back also the company had informed that USFDA has granted Fast Track Designation for Tenalisib (RP6530) to Rhizen.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

852.30 -4.95 (-0.58%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×